Email this article Current approaches to selection of the 1st line therapy in patients with metastatic hormone-sensitive prostate cancer
- Authors: Alekseev B.Y.1, Andrianov A.N.2, Kaprin A.D.1
-
Affiliations:
- National Medical Research Radiology Center, Ministry of Health of Russia
- N.N. Lopatkin Scientific Research Institute of Urology and Interventional Radiology – branch of the National Medical Research Radiology Center, Ministry of Health of Russia
- Issue: Vol 13, No 4 (2017)
- Pages: 85-90
- Section: DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCER
- Published: 30.12.2017
- URL: https://oncourology.abvpress.ru/oncur/article/view/770
- DOI: https://doi.org/10.17650/1726-9776-2017-13-4-85-90
- ID: 770
Cite item
Full Text
Abstract
Hormone therapy of metastatic prostate cancer (mPC) has been the “golden standard” of treatment since 1941. However, survival rates in patients with this pathology have remained low. Based on the results of newer studies, early start of docetaxel chemotherapy or antiandrogen abiraterone therapy in combination with standard hormone therapy allows to significantly increase survival of patients with mPC. In this review, data from these studies and advisability of docetaxel and abiraterone at the 1st line therapy of mPC are discussed.
About the authors
B. Ya. Alekseev
National Medical Research Radiology Center, Ministry of Health of Russia
3 2nd Botkinskiy Proezd, Moscow 125284
Russian FederationA. N. Andrianov
N.N. Lopatkin Scientific Research Institute of Urology and Interventional Radiology – branch of the National Medical Research Radiology Center, Ministry of Health of Russia
Author for correspondence.
Email: mailandrianov@gmail.com
Build. 1, 51 3rd Parkovaya St., Moscow 105425
Russian FederationA. D. Kaprin
National Medical Research Radiology Center, Ministry of Health of Russia
3 2nd Botkinskiy Proezd, Moscow 125284
Russian FederationReferences
Supplementary files
